Title: A prospective Low-Interventional Phase 4 Single Arm Study of Ocular Assessments in Patients treated with Tivdak in Recurrent or Metastatic Cervical Cancer (GOG 3116)
Purpose: The purpose of this study is to learn about possible side effects of TIVDAK, especially to any side effect that is related to the eye. A side effect is anything a medicine does to your body that is not part of how the medicine treats disease.
Principle Investigator: Christen Haygood, M.D.
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Recruiting
Title:
Purpose:
Principle Investigator: Christen Haygood, M.D.
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Recruiting
Title: A Randomized, Multicenter, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E)
Purpose: The purpose of this study is to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Principle Investigator:
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Active, not recruiting
Title: A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)
Purpose: The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.
Principle Investigator: Christen Haygood, M.D.
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Recruiting
Title: A Phase 3 Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone as First-line Maintenance Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (TroFuse-033/GOG-3119/ENGOT-en29)
Purpose: The goal of this study is to learn if people who receive sac-TMT with pembrolizumab live longer and without the cancer getting worse compared to people who receive pembrolizumab alone.
Principle Investigator: Christen Haygood, M.D.
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Recruiting
Title: Vaginal Fluid Collection Study for Endometrial Cancer Test Research and Development
Purpose: The primary objective of this study is to obtain de-identified vaginal fluid specimens from participants with an endometrial tissue biopsy-based histopathological diagnosis of endometrial cancer (EC), endometrial hyperplasia (AEH) with atypia or endometrial intraepithelial neoplasia (EIN).
Principle Investigator: Christen Haygood, M.D.
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Recruiting
Title: A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial of Selinexor in Maintenance Therapy After Systemic Therapy for Patients With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
Purpose: The purpose of this study is to evaluate the efficacy and safety of selinexor as a maintenance treatment in patients with p53 wt endometrial carcinoma (EC), who have achieved a partial response (PR) or complete response (CR) (per Response Evaluation Criteria in Solid Tumors version 1.1 [RECIST v 1.1]) after completing at least 12 weeks of platinum-based therapy. A total of 276 participants will be enrolled in the study and randomized in a 1:1 ratio to maintenance therapy with either selinexor or placebo.
Principle Investigator: Christen Haygood, M.D.
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Recruiting
Title: Merck- GOG 3036 Study
Purpose: A Randomized Phase 3, Double-Blind Study to assess the efficacy and safety of treatment with carboplatin/paclitaxel* PLUS pembrolizumab (MK-3475) and maintenance olaparib (MK-7339) in women with epithelial ovarian cancer (EOC), fallopian tube cancer, or primary peritoneal cancer.
Study Location: Jackson Heart Clinic and St. Dominic Jackson Memorial Hospital.
Principle Investigator: Dr. Donald Seago and Dr. Christy Haygood
Contact: For more information, please contact the research office at (225) 765-7659 or via email at research@fmolhs.org.
Open for Enrollment
